Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus versus Advagraf in kidney transplant recipients
2023-503531-18-00Phase 4Authorised
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Sep 2023
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in kidney transplant immunosuppression (2 arms), sponsored by Universitätsklinikum Regensburg. Primary endpoint: Dose-normalised trough level (C/D ratio). Planned start Sep 2023; status: authorised.
02
Drugs
tacrolimus
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2023-503531-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503531-18-00.